BioSpace News Archive

PerkinElmer, Inc. (NYSE:PKI) today announced the launch of two Research Use Only (RUO) solutions, PKamp™ VariantDetect™ SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit.

Longeviti Neuro Solutions, a medtech company developing innovative solutions for complex brain surgery, today announced the launch of the Longeviti ClearFit Cover

- Initial data from Phase 1 of the study expected by the end of Q2 2021, subject to rate of enrollment - Adaptive Phase 1/2 study supported by previously announced contribution from Strategic Innovation Fund of Canadian Government of up to CAD$56 million - Initiation of Phase 1/2 study of pan-coronavirus vaccine candidate, VBI-2901, anticipated later in 2021

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, announced today that it has promoted long-time officer Shishir Sinha to the newly created position of Chief Operating Officer.

Artelo Biosciences, Inc. (NASDAQ: ARTL ) , a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors.

Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative disease using nanocatalysis, today announced that over 50% of participants have been enrolled in the HEALEY ALS Platform Trial being conducted at sites of the Northeast ALS (NEALS) consortium.

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today is updating the market on the Company’s key scientific achievements reported in Zoonotic Anticipation

Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter solutions developed on a robust intellectual property platform, designed to connect People and Things, has appointed Dr. Raafat Mansour to its Technical Advisory Committee.

Today, Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts , announced a deal with Shanghai Haohai Biological Technology Ltd. (“Haohai”) that will result in a $32 million Series A Preferred Stock investment into Eirion along with exclusive licenses that will be for all of Eirion’s products

Selexis SA and Boston Immune Technologies and Therapeutics (BITT) have entered into a service agreement to develop the cell line for BITR2101, BITT’s lead tumor necrosis factor receptor 2 (TNFR2) antagonist antibody for the treatment of cancers and infectious diseases.